Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study.

AIDS (London, England) - 7 Jul 2000

Durant J, Clevenbergh P, Garraffo R, Halfon P, Icard S, Del Giudice P, Montagne N, Schapiro J M, Dellamonica P

Abstract excerpt

OBJECTIVE: In a prospective randomized study, the impact of plasma protease inhibitor (PI) trough levels on changes in HIV RNA were assessed in patients treated with genotypic-guided therapy. METHODS: Patients failing combination therapy (HIV-1 RNA > 10,000 copies/ml, and at least 6 months of the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Microbial
Share to Genotype
Share to HIV-1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Infections

Share to HIV Protease Inhibitors

Share to RNA, Viral

Share to Treatment Failure

Source

Identifiers

PMID: 10930147
DOI: 10.1097/00002030-200007070-00005

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-10930147-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study.PMID 10930147Read ↗

Protease inhibitor resistance in HIV-infected patients: Molecular and clinical perspectivesSemantic proximity Read ↗

Navigating HIV-1 drug resistance: A comprehensive review of protease inhibitor efficacy and mutation dynamics.Semantic proximity Read ↗

PharmAdapt: a randomized prospective study to evaluate the benefit of therapeutic monitoring of protease inhibitors: 12 week results.Semantic proximity Read ↗

HIV-1 protease inhibitors: effects on HIV-2 replication and resistanceSemantic proximity Read ↗

Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial.Semantic proximity Read ↗

Principles and practice of HIV-protease inhibitor pharmacoenhancement.Semantic proximity Read ↗

HIV protease mutations leading to reduced inhibitor susceptibility.Semantic proximity Read ↗

GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy.Semantic proximity Read ↗

A randomized controlled trial to evaluate antiretroviral salvage therapy guided by rules-based or phenotype-driven HIV-1 genotypic drug-resistance interpretation with or without concentration-controlled intervention: the Resistance and Dosage Adapted Regimens (RADAR) study.Semantic proximity Read ↗

Therapeutic drug monitoring and human immunodeficiency virus (HIV) antiretroviral therapy.Semantic proximity Read ↗

Pharmacokinetic Parameters of HIV-1 Protease Inhibitors.Semantic proximity Read ↗

Impact of protease polymorphisms and viral fitness on human immunodeficiency virus (HIV) type 1 viremia in untreated HIV-1 infection.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.